Sanofi News

6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines

Dec 23, 2024 14:11 ET

6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Dec 20, 2024 06:10 ET

6-K: Colletion of Recent Announcements

Dec 13, 2024 11:11 ET

6-K: Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma and Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria

Nov 18, 2024 12:26 ET

6-K: Dupixent Approved in the EU as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Nov 7, 2024 11:38 ET

6-K: Dupixent Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

Oct 31, 2024 07:00 ET

6-K: Sanofi and Orano Join Forces to Develop Next-Generation Radioligand Medicines and Sanofi and CD&R Partner to Fuel Opella's Ambitions in Consumer Healthcare

Oct 21, 2024 11:50 ET

6-K: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants and Sanofi in discussions to sell a controlling stake in Opella

Oct 11, 2024 15:39 ET

6-K: Dupixent Approved in China as the First-Ever Biologic Medicine for Patients with COPD and Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD

Oct 2, 2024 11:09 ET

6-K: Colletion of Recent Announcements

Sep 24, 2024 14:57 ET

6-K: Colletion of Recent Announcements

Sep 13, 2024 12:51 ET

6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis

Sep 3, 2024 10:51 ET

6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

Aug 13, 2024 06:10 ET

6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A

Jul 23, 2024 11:29 ET

6-K: Colletion of Recent Announcements

Jul 2, 2024 14:30 ET

6-K: Colletion of Recent Announcements

Jun 11, 2024 13:58 ET

6-K: Sanofi Completes Acquisition of Inhibrx, Inc

May 30, 2024 16:37 ET

6-K: Colletion of Recent Announcements

May 28, 2024 12:06 ET

Sanofi | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Apr 4, 2024 08:50 ET

Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis

Mar 20, 2024 14:13 ET